INTRODUCTION
During platelet activation a number of proteins undergo tyrosine phosphorylation (Ferrell and Martin, 1988; Golden and Brugge, 1989; Nakamura and Yamamura, 1989) . Several reports indicate that aggregation contributes to this increase in tyrosine phosphorylation, and implicate the major fibrinogen receptor, glycoprotein Ilb/Illa, in this process (Ferrell and Martin, 1989; Golden et al., 1990) . The non-integrin gpIV, a putative thrombospondin/collagen receptor, has also been implicated in tyrosine kinase activation (Huang et al., 1991) . In addition, activation of protein kinase C and mobilization of Ca2+ is also associated with increased tyrosine phosphorylation (Takayama et al., 1991) .
Phospholipase Cy (PLCy) contains the src homology domain SH2, which is involved in protein clustering through binding to tyrosine-phosphorylated regions of other proteins (Matsuda et al., 1990; Mayer et al., 1991) . These interactions potentially regulate the activity of PLCy. In addition, PLCy1 has been shown to undergo tyrosine phosphorylation at three distinct sites (Rhee, 1991) , and this has been linked to an increase in catalytic activity (Nishibe et al., 1990) . PLCy1, and in lower levels PLCy2, have been identified in human platelets (Banno et al., 1992) although it is not known whether either species undergoes tyrosine phosphorylation on platelet activation.
We sought a method of inducing tyrosine phosphorylation in platelets in order to study its consequences for regulation of PLC and functional responses. Inazu et al. (1990) demonstrated that a peroxovanadate complex {diperoxo-orthovanadate;
[VO2(02)2j31-, formed in solutions of orthovanadate and H202 (Greenwood and Earnshaw, 1984) , induces high levels of protein tyrosine phosphorylation in association with platelet activation. We have therefore used peroxovanadate to investigate whether protein tyrosine phosphorylation stimulates PLC activity in platelets and whether this underlies the mechanism of platelet activation by the vanadate complex.
MATERIALS AND METHODS

Reagents and antibodies
Ro 31-8220 was a gift from Roche Products (Welwyn Garden of nearly all proteins and inhibits completely all other functional responses, suggesting that these events may be linked. In support of this, peroxovanadate stimulates tyrosine phosphorylation of phospholipase Cyl, suggesting that this may underlie its mechanism of platelet activation. Staurosporine also inhibited activation of phospholipase C by collagen, suggesting that tyrosine phosphorylation has an important role in the early stages of collagen-induced platelet activation.
City, Herts., U.K.). Anti-pp60src and rabbit anti-PLCyl antibodies were gifts from Dr. J. Brugge (Philadelphia, U.S.A.) and Dr. T. Pawson and Dr. C. Ellis (Toronto, Canada) respectively. Anti-phosphotyrosine mouse monoclonal antibody was purchased from ICN Flow (High Wycombe, Bucks., U.K.). Staurosporine was from Sigma (Poole, Dorset, U.K. 
Platelet preparation and experimentation
Blood was drawn on the day of the experiment from aspirin-free volunteers, and sterile 20 mM sodium citrate was used as anticoagulant. Platelet-rich plasma was obtained by centrifugation at 200 g for 20 min. Platelets were isolated from platelet-rich plasma by centrifugation at 1000 g for 10 min in the presence of prostacyclin (0.1 ,ug/ml), used to increase intracellular cyclic AMP. Platelets were resuspended at 37 'C in 1 ml of modified Tyrode-Hepes medium (composition in mM: NaCl 138, NaH2PO4 0.36, KCI 2.9, NaHCO3 12, Hepes 20, glucose 5, (Nunn and Watson, 1987) .
Immunoblotting
Samples were heated in Laemmli buffer at 80°C for 30 min.
Proteins were separated by SDS/PAGE (100% gels) and transferred to polyvinylidene difluoride (PVDF; Immobilon P; Millipore) blotting membranes by semi-dry transfer (90 min, 15 V).
Non-specific binding was blocked with 5 % BSA in TBS-T (Tris 20 mM, NaCl 137 mM, Tween-20 0.1 %, pH 7.6), before probing with the primary antibodies PY20 (anti-phosphotyrosine) or aPLCy (Decker et al., 1990) . Blots were washed five times in TBS-T before detection of bound antibody with horseradishperoxidase-conjugated sheep anti-mouse IgG (NA 931; Amersham), or donkey anti-rabbit IgG (NA 934). After further washing, the membranes were treated with Amersham ECL reagents, and exposed to ECL-hyperfilm.
Blots were stripped of bound antibody by washing in TBS-T containing 20% SDS at 80°C for 30 min. The blot was then washed five times with TBS-T, and the stripping of antibody was verified by re-probing with horseradish-peroxidase-conjugated anti-IgG secondary antibody and ECL detection. Blots were then re-blocked and re-probed as detailed above.
Immunoprecipitation
Platelets were lysed on ice for 1 h with an equal volume of icecold extraction buffer consisting of 20% Triton X-100, 0.250% sodium deoxycholate, 10 mM EDTA, 100 ,uM Na3VO4, 100 mM Tris, 1 mM phenylmethanesulphonyl difluoride, 10 mM NaF, 1 mg/ml DNAase 1 and 20 ,tM cytochalasin B at pH 7.6. All subsequent steps were carried out at 4 'C. 140 kDa. This pattern of increased tyrosine phosphorylation is in reasonable agreement with that described by Inazu et al. (1990) in platelets challenged with peroxovanadate. The major band of 54 kDa co-migrated with a protein detected by a monoclonal antibody to pp6O8rc (Golden et al., 1986 ) and may represent a proteolytic degradation product of pp6osrc (Rendu et al., 1991) .
Increased protein phosphotyrosine was detectable within 5 s of addition of H202 and vanadate (Figure 1) , and preceded the increase in phosphorylation of pleckstrin (47 kDa), the major substrate of protein kinase C, and myosin light chains (MLC; 20 kDa), which are phosphorylated at distinct sites by MLC kinase and protein kinase C (Figure lb) . Tyrosine phosphorylation appeared to reach an early plateau within 20 s, which was maintained for up to 120 s, followed by a further increase between 120 and 300 s (Figure la) . We used the kinase inhibitors staurosporine and Ro 31-8220 to investigate whether peroxovanadate directly induces tyrosine phosphorylation or whether this is secondary to activation of protein kinase C. Staurosporine is a relatively non-specific (a) (kDa) inhibitor of both serine/threonine and tyrosine kinases (Watson et al., 1988; Geissler et al., 1990) , whereas Ro 31-8220 is an analogue of staurosporine with increased selectivity for protein kinase C (Davis et al., 1989; Walker and Watson, 1993 although the 54 kDa protein was a notable exception in that its phosphorylation was only inhibited partially ( Figure 2 ). In contrast, a maximally effective concentration of Ro 31-8220 (10 M) completely inhibited phosphorylation of the 47 kDa protein induced by peroxovanadate, but only decreased partially the phosphorylation of MLC and had no apparent effect on tyrosine phosphorylation (Figure 2 ). The partial inhibition of phosphorylation of MLC by Ro 31-8220 is thought to reflect inhibition of the protein kinase C-mediated component of phosphorylation (Walker and Watson, 1993) . These results provide further evidence for the selectivity of Ro 31-8220 as an inhibitor of protein kinase C and confirm the non-selectivity of staurosporine.
Functional responses
The increase in tyrosine phosphorylation induced by orthovanadate (400 uM) and H202 (4 mM) was associated with shape change, aggregation and secretion responses (Figure 3) . On its own, vanadate (400,M) had no effect on functional responses, whereas occasionally H202 (4 mM) appeared to produce a transient decrease in light transmission, which may reflect effervescence. The onset of shape change and aggregation lagged behind the early increase in tyrosine phosphorylation and appeared to occur in parallel with phosphorylation of 20 kDa and 47 kDa proteins (Figures 1 and 3 ). Similar results (not shown) were seen in platelets treated with indomethacin. Aggregation, shape change and [3H]5-HT secretion induced by peroxovanadate were inhibited completely by staurosporine (10 ,uM) , suggesting that these responses are initiated by tyrosine phosphorylation (Figure 3) degree of secretion (Figure 3) . The inhibitory action of Ro 31-8220 is similar to that described previously against thrombininduced activation of platelets (Walker and Watson, 1993 (Watson et al., 1988; Walker and Watson, 1993 (Walker and Watson, 1993) . The results therefore demonstrate that the early increase in tyrosine phosphorylation induced by peroxovanadate is not mediated through activation of protein kinase C, nor through the onset of aggregation or secretion.
Activation of platelets by peroxovanadate is associated with increased tyrosine phosphorylation of PLCyl, suggesting that this may underlie the increase in formation ofinositol phosphates and onset of functional responses. The ability of various receptor tyrosine kinases, e.g. receptors for epidermal growth factor and platelet-derived growth factor, to induce formation of inositol phosphates is also associated with increased tyrosine phosphorylation of PLCy (Meisenhelder et al., 1989; Decker et al., 1990; Goldschmidt-Clermont et al., 1991) , and tyrosine phosphorylation of PLCy has been reported to increase its catalytic activity (Nishibe et al., 1990) . Alternatively, the general increase in tyrosine phosphorylation in platelets induced by peroxovanadate may provide a suitable membrane anchor for the SH2 domain of PLCyl, thereby leading to its activation. Tyrosine phosphorylation of certain platelet proteins during physiological stimulation requires the integrity of platelet integrin receptors and other receptors which bind the RGD peptide sequence (Ferrell and Martin, 1989; Golden et al., 1990) . It is an attractive hypothesis that binding of fibrinogen, thrombospondin or other proteins to these receptors during primary aggregation stimulates secondary PLC activity through tyrosine phosphorylation of PLCy1. Similarly, the inhibition of collagen-stimulated PLC activation by staurosporine observed in the present study may suggest that tyrosine kinase activity has an important role in the early stages of collagen-induced platelet activation.
In conclusion, we have demonstrated that peroxovanadate causes the tyrosine phosphorylation of platelet PLCyl, stimulation of PLC activity, and platelet activation. The physiological significance of this remains to be determined.
